The effects of the centrally acting anti cholinesterase metrifonate (MFT) and its metabolite dichlorvos (2,2-dichlorovinyl dimethyl phosphate; DDVP) on local cerebral glucose utilization (LCGU) have been studied in 3-and 27-month-old rats, using the auto radiographic [14C]deoxyglucose technique. In 3-month old rats, MFT (80 mg/kg i.p.) increased LCGU signifi cantly in 17 of the 54 regions studied, including insular, cingulate, and temporal cortices, ventral hippocampus, thalamus, lateral habenula, substantia nigra, and superior colliculus. In these regions, the average MFT-induced in crease in LCGU was 23% above control. The average hemispheric LCGU increased by 10% (p < 0.01). DDVP (5 mg/kg) increased LCGU in 19 regions (average in crease 26%), The average hemispheric LCGU increased by 9% (p < O.O\). Regional distributions of MFT-and DDVP-induced increases in LCGU were similar and overlapped the distribution of the acetylcholinesterase activity. In 27-month-old rats, MFT was active in 18 re gions (average increase 25%), The whole-brain mean LCGU increased by 10% (p < O.O\), MFT compensated for the age-related hypometabolism in some brain areas including insular, temporal, and retrosplenial cortices, substantia nigra, and superior colliculus. The effects of MFT on LCGU were preserved in old rats, at variance with other anticholinesterases (tacrine, physostigmine), which are less active in the aged rat brain.
One of the earliest and most characteristic changes in Alzheimer's disease (AD) is a decreased level of cholinergic markers in cortical areas and subcortical cholinergic nuclei (Whitehouse et at., 1982) . This cholinergic deficit correlates with the degree of memory impairment of AD patients. A possible therapeutic approach in AD may be to compensate for the loss of central cholinergic neu rons by potentiating the activity of the remaining intact neurons. This can be achieved by inhibitors of acetylcholinesterase (AChE), the hydrolytic en zyme of acetylcholine (ACh), making more ACh available to postsynaptic neurons. A number of studies report that cholinesterase inhibitors such as physostigmine (PHY) and the recently approved agent tacrine (tetrahydroaminoacridine; THA) are moderately effective in some mildly demented AD patients (for review see Lamy, 1994) , However, the therapeutic effects of PHY and THA are limited in terms of both number of responders and quality of improvement.
There is a need for other agents that ideally would be effective in a larger number of patients, would have a long duration of action, and would be devoid of adverse effects, The organophosphorus com pound metrifonate (MFT) is a member of the so called second generation of cholinergic AD thera peutics. Dichlorvos (2,2-dichlorovinyl dimethyl phosphate; DDVP), hydrolyzed nonenzymatically from MFT, is the active AChE-inhibiting principle. Based on results obtained in the rat, Hallack and Giacobini (1989) suggested that MFT might be more likely to produce therapeutic effects than other an ticholinesterase compounds, because of its long du ration of action, low rate of side effects, and capa-bility to reach high levels of AChE inhibition (Nord gren et aI., 1978; Hallack and Giacobini, 1987 ). An open trial study gave evidence that MFT improves cognitive performance in AD (Becker et aI., 1990) . Further studies are required to confirm the efficacy of MFT and to determine its mechanisms of action. One way of investigation is to assess the effect of MFT on cerebral metabolism. The therapeutic ef fect of MFT might involve an effect on local cere bral glucose utilization (LCGU). Indeed, LCGU de creases in a number of brain areas in AD patients (Benson et aI., 1983; de Leon et aI., 1983; Foster et aI., 1984) . There is evidence that THA increases LCGU in AD patients in brain areas such as parietal and temporal cortex, which show the most consis tent alterations in AD (Nordberg et aI., 1992; Nord berg, 1993) . The aims of the present study were to analyze the effects of MFT and DDVP on LCGU in young rats and to compare these results with those obtained in aged rats where reductions in brain me tabolism occur (Smith et aI., 1980; Wree et aI., 1991; Bassant et aI., 1994) to determine whether MFT-induced changes in LCGU observed in young rats are also found in a situation of age-related hy pometabolism.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats were obtained from IFF A Credo (France). Forty-two rats aged 3 months (body wt 280 ± 21 g) were used. The rats were housed at 22°C under a 12-h light/dark cycle and had free access to water and food. Aged rats (27 months, 730 ± 120 g) were ob tained at 24 months of age and housed in our animal fa cility for 3 months (three animals per cage). Approxi mately 40% survived to an age of 27 months. None of the sixteen aged rats used in the experiment had apparent tumor mass. Two had pituitary adenoma.
Chemicals
MFT is not by itself an AChE inhibitor. Nonenzymatic metabolism (dehydrochlorination) of the agent is required to form the active component dichlorvos, which is an irreversible cholinesterase inhibitor. MFT and DDVP were obtained from Bayer AG-Tropon (Germany). PHY, hexamethonium bromide, and atropine methylbromide were obtained from Sigma (France). [14CJ2-DeoxY-D glucose ([14CJDG; specific activity 50-55 mCi/mmol) in ethanol was purchased from Amersham (France). The so lution was evaporated under nitrogen, and r 14C]DG was resuspended in isotonic saline.
Measurement of LCGU
LCGU was measured by the quantitative [14C)DG tech nique of Sokoloff et al. (1977) . Following 16 h of food deprivation, rats were lightly anesthetized (I % halothane in oxygen) and catheters were inserted in a femoral vein and artery. The operative sites were infiltrated with 1% xylocaine and closed with wound clips. Rats were placed in a loose-fitting plaster body cast in which the hindlimbs were restrained, permitting free movements of the head and forelimbs. Body temperature was monitored via a rectal thermoprobe connected to a thermostatic device (Harvard, UK) that activated an external warming ele ment when body temperature fell below 35.5°C. Mean arterial blood pressure and heart rate were assessed be fore and at fixed times after drug treatment by connecting the arterial catheter to a pressure transducer (Barovar; Alvar Electronic, France), which was attached to a paper chart recorder (Gould, U.S.A.). Baseline and subsequent measurements of plasma glucose concentration were made throughout the experiment (Glucose Analyzer II; Beckman, U.S.A.). Hematocrit was determined prior to the injection of ['4C)DG. Animals were excluded from the study if baseline values were outside of the following lim its: mean arterial pressure 90-130 mm Hg, temperature 35-38°C, plasma glucose concentration 100-200 mg/dl.
After a 4-h recovery period, [14C)DG 125 fJ.Cilkg was administered by rapid intravenous bolus injection. Arte rial blood samples (100 fJ.1) were taken at 6, 18, 30 s and I, 3, 5, 7.5, 15, 25, 35 , and 45 min after rl4CJDG injection. Samples were centrifuged immediately and plasma radio activity (liquid scintillation counter 1209; LKB Wallac, U.S.A.) and glucose concentration were measured. Ani mals were killed 45 min after [14C)DG by an overdose of pentobarbital. Brains were removed rapidly and frozen in isopentane chilled with dry ice at -45°C, then stored at -70°C. Coronal brain sections (20 fJ.m thick) were cut on a cryostat (Reichert-lung, Cambridge Instrument, Ger many) at -20°C. Sections were mounted on coverslips and dried immediately at 55°C on a hot plate. Autoradio graphs were then prepared by exposing X-AR5 x-ray film (Kodak) to the mounted sections and ['4C)methyl methacrylate standards (Amersham) for 7 days.
Autoradiograms were analyzed by quantitative densi tometry with a computerized image-processing device (Biocom, France). To identify brain structures and corti cal layers, sections adjacent to those used for autoradi ography were stained with cresyl violet. Stained sections and corresponding sections in the autoradiogram were superimposed and the delineation of the structures was made according to the atlas of Paxinos and Watson (1986) . The neocortex was divided into superficial layers (layers I, II, and upper part of layer III), middle layers (lower part of layers III and IV), and deep layers (layers V and VI). Five separate optical density measurements for each structure were made in consecutive brain sec tions. For each rat and each brain region, LCGU value was calculated as the arithmetic mean of five independent measurements. As right-left differences were sometimes found, only measurements in the left hemisphere were considered. Tissue 14C concentrations were determined from the optical densities and a calibration curve obtained by a densitometric analysis of the autoradiograms of the calibrated standards. LCGU was then calculated from the local tissue 14C concentrations, the time course of the plasma [14CJDG and glucose concentration, and appro priate kinetic constants according to the operational equation published by Sokoloff et al. (1977) .
Time course of drug effects
To inject the rl4C)DG atthe peak of the drug effects, a pilot experiment had been performed to determine the time course of the behavioral effects of MFT and DDVP. Young rats received an intraperitoneal injection of MFT (80 mg/kg; n = 5) or DDVP (5 mg/kg; n = 5). Control rats (n = 5) received an equal volume of saline. Central body temperature was assessed at fixed times (10 min) during 2 h. Behavioral signs (tremor, gnawing, teeth chattering) were quantified at fixed times by a single experimenter who rated each animal on a scale of 0 (no effect) to + + + (maximum effect). On the basis of these observations (data not shown) MFT and DDVP were respectively in jected 30 and 5 min before ['4C]DG. The same experiment was repeated in 27-month-old rats with MFT (80 mg/kg).
As compared with 3-month-old rats, the time course and the amplitude of the behavioral effects were the same in aged rats. Therefore, the same schedule of drug adminis tration was used in the aged rats.
Drug treatments
To block the peripheral effects of anticholinesterases, animals were pretreated with hexamethonium bromide (5 mg/kg i.p.) and atropine methyl bromide (4 mg/kg s.c.), respectively, 30 and 20 min before drug administration. Animals then received an intraperitoneal injection of iso tonic saline (control group) or MFT (freshly prepared, pH 6.0) or DDVP. Under acidic conditions, the rate of de composition of MFT into DDVP is very slow and can be considered as negligible. In 3-month-old rats, LCGU was assessed in six groups of seven rats: control group, MFT 50 or 80 mg/kg 30 min before ['4C]DG, DDVP 5 mg/kg 5 min before ['4C]DG; to assess early or late effects, MFT (80 mg/kg) was also administered \0 min or 2 h before [14C]DG. In 27-month-old rats, LCGU was assessed in two groups of eight rats: control and MFT 80 mg/kg 30 min before ['4C]DG.
Statistical analysis
Physiological parameters were compared between age matched control and treated rats by one-way analysis of variance (ANOVA), followed by the Scheffe method.
Within each experimental group, physiological parame ters at different times after ['4C]DG were compared using paired-sample t test.
For each brain region, LCGU values were analyzed as follows: Three-month-old control rats and the five groups of MFT-or DDVP-treated rats were compared by one way ANOVA followed by Dunnett's test for multiple comparisons. The 27-month-old control and treated rats were evaluated by ANOV A followed by the Scheffe method. Then LCGU values were subjected to two-way ANOVA (region, drugs). Values from 3-and 27-month old treated rats were compared by one-way and two-way ANOVA (age, treatment). Differences were considered significant if p < 0.05.
RESULTS
Physiological parameters during e4C]DG experiment
As compared with age-matched control rats (Ta ble 1), body temperature significantly decreased in MFT-treated rats. Plasma glucose concentration in creased in 27-month-old MFT-treated rats. As com pared with the baseline conditions (before [14C]DG), body temperature decreased and plasma glucose concentration increased in MFT-treated rats of both ages. However, physiological parame ters in treated rats were within the required limits of Sokoloff's method.
LCGU in 3-month-old rat
Effects of MFT 30 min. before £,4C]DG. MFT (50 mg/kg) significantly increased LCGU in the insular and temporal cortex and in the thalamus, lateral habenula, and substantia nigra pars compacta (7 of the 54 regions studied) ( Table 2) . A higher dose of MFT (80 mg/kg) produced a larger metabolic acti vation. LCGU significantly increased in 17 of the 54 regions studied (Tables 2-5 ). In these regions, LCGU increased by 23% as compared with con trols. In addition to the regions where changes were observed after the 50-mg/kg dose, increases in LCGU were found in the superior colliculus (50%), the cingulate (19%) and retrosplenial cortex (16%), the preoptic area (21 % (Reiner et al., 1975) . However, some authors consider that MFT itself has anticholinesterase properties (Bueding et al., 1972) . The effects of DDVP on LCGU were mea sured and compared with those of MFT to deter mine whether the effects of MFT on LCGU were similar to or different from those of its metabolite. DDVP (5 mg/kg) was administered 5 min before [14C]DG because of its short duration of action. In creases in LCGU were observed. in 19 regions (av erage increase of 26%) ( Table 2 ). The average hemi spheric LCGU increased by 9% (p < 0.01). Large metabolic activations were observed in the superior colliculus (69%), the ventral thalamus (40%), the interpeduncular nucleus (32%), and the basolateral amygdala (31%) (Fig. 3 LCGU in 27-month-old rats LCGU in 27-month-old rats under basal condi tions. As compared with 3-month-old rats, the av erage hemispheric LCGU was significantly reduced by 10% (p < 0.01) in 27-month-old rats (78 ± 22 and 70 ± 20 j.1moll00 g-I min-I respectively). LCGU reduction in aged rats was not evenly distributed in the brain but restricted to specific regions (20 of the 54 regions studied) (Tables 3-5). In these regions, LCGU decreased by 10-24% in aged rats as com pared with young controls (average decrease of 17%). Significant decreases were found in cortical areas (prefrontal, insular, retrosplenial, occipital, (Tables 3-5 ).
In these regions, average MFT-induced increase in LCGU was 25% with respect to the age-matched controls. In cortical areas, the largest effects were found in the insular (35%), temporal (33%), and ret rosplenial (23%) cortices ( Figs. I and 2 ). In the sub cortical areas, pronounced effects were observed in the superior colliculus (80%), the ventral thalamus (31%), the lateral habenula (17%), and the ventral hippocampus (15%) (Fig. 2) . In the 20 regions where a significant age-related decrease in LCGU occurred (Tables 3-5), MFT was active in nine regions where it compensated for the age-related decrease in LCGU (temporal cortex) or exceeded the young control values (substantia nigra pars reticulata, insular and retrosp\enial cortices, superior colliculus) (Fig. 4) . Effects of MFT in 27-month vs. 3-month-old rats.
Average hemispheric increase in LCGU (10.5 vs. 10%), number of affected regions (17 vs. 18), and average increase in LCGU in the affected regions (23 vs. 25%) were similar in young and aged MFT treated rats. Two-way ANOV A did not show sig nificant interaction between age and treatment. Effect of MFT was no longer observed in the baso lateral amygdala, the substantia nigra (pars com pacta), or the interpositus nucleus. On the other hand, significant increases were found in the piri form and perirhinal cortices, the ventral hippocam pus (CAl field), and the substantia nigra (pars retic ulata). Comparison with other AChE inhibitors. The ef fects of PHY and THA have previously been stud ied in the aged rat under identical experimental conditions (Bassant et aI., 1995) . Results can be summarized as follows: After THA, average hemi spheric LCGU increased by 5% (n.s. ), 13 of 54 brain regions were affected (average increase of 24%). After PHY, average hemispheric LCGU in creased by 7% (p < 0.05); 10 brain regions were affected (average increase of 23%). As compared with those of 3-month-old rats, the effects of THA and PHY were significantly weaker in aged rats. MFT was somewhat more potent than the other two drugs, in terms of both magnitude of the increase in LCGU and number of regions involved (Fig. 5 ). PO, preoptic area (magnocellular) . Notice that the topography of the effects is similar in 3-and 27-month-old rats. In the insular cortex, MFT increases LCGU to a level that exceeds that of the young controls in spite of the age-related hypometabolism.
DISCUSSION
Effects of MFT on LCGU in 3-month-old rats
MFT increases LCG U in a sizable number of brain regions in the young rat, in a dose-dependent manner. DDVP, the active metabolite of MFT, which is an irreversible cholinesterase inhibitor, has similar effects. This finding indicates that the MFT induced metabolic activation is probably due to the anticholinesterase properties of DDVP. In addition, the effects of MFT have a regional topography sim ilar to that observed with PHY, a reference cholin esterase inhibitor (Bassant et ai., 1993) . As antici pated, a large majority of the regions where MFT increases LCGU (14 of 17) have a high AChE ac tivity (Mash and Potter, 1986; Paxinos and Watson, 1986) . The correlation, however, is not perfect be cause some regions with a high AChE activity, such as striatum and medial septal area, are not affected by MFT. LCG U increases in the interpositus nu-deus, a structure that receives few cholinergic fi bers (Goldsmith and Van Der Kooy, 1988) but is involved in the control of muscular activity. The effect observed in the interpositus might be due to the muscular hyperactivity (tremors) induced by MFT rather than to a specific effect on cholinergic transmission.
Results from in vivo and in vitro experiments in dicate that glucose utilization, as measured with [14C]DG method, occurs more in the neuropil (re gion enriched in axon terminals, dendrites, syn apses, and astrocytic processes) than in the neuro nal perikarya (Magistretti et ai., 1995) . In case of functional activation, however, the increase of LCGU in the perikaryal layers is positively corre lated with an increase of LCGU in their associated neuropil-rich layers (Wree et at., 1988) . Several ob servations strongly suggest that astrocytes are the cells where glucose uptake occurs during activa tion. In astrocytes, glucose is metabolized into lac tate, which is taken up by neurons and serves as CONTROL MFT substrate for oxidative phosphorylation (see ref.
in Magistretti et a\., 1995) . MFT, by inhibiting AChE, causes ACh to accumulate at cholinergic receptor sites. As a consequence, several neuronal functions such as ion pumping, intracellular transports, re uptake, etc., are increased. These functions have high metabolic requirements, as shown by high level of [14C]DG uptake in MFT-treated rats. In ad dition, the activity of astrocytes, which possess muscarinic and nicotinic receptors (Rosli and Rosli, 1988) , might also be potentiated by the in creased concentration of ACh and participate in the MFT-induced increase in LCGU. MFT has been reported to improve cognitive per formances in young and old rats (van der Staay et a\., 1996) and in AD patients (Becker et a\., 1990) .
To what extent an increase in LCGU is involved in the therapeutic effects of MFT remains to be estab lished. It is interesting to note that the temporal cortex, which shows the most consistent LCGU al terations in AD (Foster et a\., 1984) , is among the regions that are the most "sensitive" to MFT in the rat. The metabolic activation observed in the sep tohippocampal system (diagonal band of Broca, ventral hippocampus) and in the cortex in the present experiment could result from an increased neuronal activity in regions involved in cognitive functions. Such an increase in LCGU might occur in AD patients receiving MFT and participate in the cognitive improvement.
The MFT-induced increase in LCGU is in the same range as that of other anticholinesterases studied under identical conditions (Bassant et aI., 1993) . MFT has no superiority to PRY and TRA with respect to metabolic activation in the young rat. Other experimental studies, however, show that it offers several advantages such as long dura tion of action, maintenance of steady-state levels of ACh in the brain, absence of decrease in the syn thesis rate of ACh, and reduced toxicity (Rallack and Giacobini, 1989; Giacobini, 1991) .
To compare the effects of MFT with those of other anticholinesterases, the doses for each drug have been determined on the basis of equivalent behavioral effects. Under these conditions, the met abolic effects of MFT and PRY were quantitatively similar, but the dose of PRY was 160-fold smaller. This finding is consistent with the stronger anti cholinesterase action of PRY (Becker and Giaco bini, 1988; Rallack and Giacobini, 1989 
Effects of MFT on LCGU in 27-month-old rats
Moderate age-related reductions of brain metab olism have been observed in humans (Kuhl et aI. , 1984; Horwitz et aI. , 1986) and in rats (Smith et aI. , 1980; Wree et aI., 1991; Bassant et aI. , 1994) . Se vere hypometabolism is a constant finding in the parietotemporal cortex of AD patients (Benson et aI. , 1983; de Leon et aI., 1983; Foster et aI. , 1984) . These alterations of LCGU might be due, at least in part, to deficits in neurotransmitter systems, includ ing the cholinergic system. It was therefore impor tant to determine if the effects of anticholinest erases on the brain metabolism observed in the young rat were still present in the aged rat, partic ularly in regions where an age-related hypometab olism occurs.
Our results show that MFT increases LCG U in several brain regions in the aged rat. As compared with young rats, the response of aged rats to MFT is similar, in terms of average hemispheric LCG U , number of regions affected, and amplitude of re gional effect. It is interesting to note that MFT is still significantly active in regions with age-related hypometabolism. For example, the hypometabo-J Cereh Blood Flow Metah. Vol. 16, No.5, 1996 lism is completely compensated by MFT in the tem poral cortex, the substantia nigra, and the interposi tus nucleus. In the insular and cingulate cortex, the ventral hippocampus, the thalamus, and the supe rior colliculus, the balance between the effect of MFT and the age-related hypometabolism results in large increases in LCG U, which exceed the young control values.
Comparison with other anticholinesterases
In a previous study, THA and PHY were found significantly less active in aged than young rats, in terms of both number of regions affected and am plitude of metabolic activation (Bassant et aI. , 1995) . What might be the reasons for this differ ence? AChE activity is not consistently affected by aging (for review, see Decker, 1987) . It seems un likely that the differences observed could be ex plained by a decrease in muscarinic receptor den sity or affinity or both because no consistent age related changes have been reported in various strains including Sprague-Dawley rats (Strong et aI. , 1980; Michaleck et aI., 1989; Schwartz et aI. , 1990) . Defective coupling of postsynaptic mecha- nisms might alter muscarinic function in the aged brain. However, Surichamorn et al. (1989) have found that phosphatidylinositol hydrolysis, in re sponse to activation of muscarinic receptors, does not change with aging in various brain areas. De creases in the number or size of basal forebrain cholinergic neurons or both have been reported in the aged rat (Biegon ct aI., 1986; Fisher et aI., 1989; de Bilbao et aI., 1991) . It is conceivable that a loss of cholinergic neurons, even moderate, and the re sulting decrease of cholinergic input to the hippo campus and neocortex could alter the effect of THA and PHY by reducing the availability of ACh at the synapse. There is also evidence that the rate of ACh synthesis decreases with advancing age (see ref. in Mc Entee and Crook, 1992) . On the other hand, studies on ACh release have shown that the depo larization-induced and the basal release of ACh are significantly decreased in synaptosomal prepara tions from aged rat brains (Araujo et aI., 1990) and that basal ACh release is decreased in cortex and hippocampus in freely moving aged rats (Wu et aI., 1988) . It is therefore possible that the efficacy of AChE inhibitors may decline with age as a result of reduced ACh release. If this is true, then the effects of MFT should have also been reduced. Are there arguments that could explain the better preservation of the effects of MFT in aged rats as compared with THA and PHY? The comparison of the effects of PHY, THA, and MFT on ACh me tabolism in young rats has shown that the greatest peak of AChE inhibition was obtained 30 min after MFT administration as compared with moderate peaks at 15 and 60 min for PHY and THA; the du ration of inhibition of AChE was four times longer after administration of equipotent doses of MFT than after PHY; and after a second dose, the in crease in levels of ACh was more significantly pro longed as compared with the first treatment with MFT, similar with PHY, and lower with THA (Hal lack and Giacobini, 1987 Giacobini, , 1989 . It is conceivable that such properties, producing a longer-lasting AChE inhibition, might partly explain the larger ef fect of MFT on LCGU in the aged brain, where the release of ACh is reduced.
Conclusions
In conclusion, MFT, like other AChE inhibitors, increases LCGU by activating cholinergic transmis sion. This effect probably plays a role in the cogni tive improvement observed after treatment of AD patients with MFT. In addition, our results show that MFT is more effective than PHY and THA in the aged rat. This original finding, consistent with some properties of the compound, and the fact that MFT has more limited side effects suggest that this drug could be particularly suitable for the treatment of the cholinergic deficit in AD.
